Synonym
ITF-1697; ITF1697; ITF 1697
IUPAC/Chemical Name
Glycyl-N(sup 2)-ethyl-L-lysyl-L-prolyl-L-arginine
InChi Key
LPKPGXJXCZNDJO-JYJNAYRXSA-N
InChi Code
InChI=1S/C21H40N8O5/c1-2-28(17(30)13-23)16(8-3-4-10-22)19(32)29-12-6-9-15(29)18(31)27-14(20(33)34)7-5-11-26-21(24)25/h14-16H,2-13,22-23H2,1H3,(H,27,31)(H,33,34)(H4,24,25,26)/t14-,15-,16-/m0/s1
SMILES Code
N=C(N)NCCC[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CCCCN)N(C(CN)=O)CC)=O)CCC1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
484.60
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction).. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J. 2004 Mar;25(5):392-400. PubMed PMID: 15033251.
2: Syeda B, Kiss K, Modarressy K, Schönau K, Schukro C, Derntl M, Laggner A, Sochor H, Glogar D. Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: a randomised, placebo-controlled pilot trial. Drugs R D. 2004;5(3):141-51. PubMed PMID: 15139775.
3: Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, Maruyama S, Bertuglia S, Mascagni P, Goligorsky MS. Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia. Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F713-21. doi: 10.1152/ajprenal.00541.2011. PubMed PMID: 22160777; PubMed Central PMCID: PMC3311315.
4: Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D, Cremonesi P, Bhattacharya J, Mascagni P. ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation. Mol Med. 2007 Nov-Dec;13(11-12):615-24. PubMed PMID: 17948065; PubMed Central PMCID: PMC2034195.
5: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.
6: Di Pierro F, d'Atri G, Marcucci F, Leoni F. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J Pharmacol Toxicol Methods. 1997 Mar;37(2):91-6. PubMed PMID: 9174984.
